Those suffering from metastatic colorectal cancer will soon have another option that could improve their survival rates and extend their lives. HUTCHMED’s partner, global pharmaceutical firm Takeda, has obtained approval from the US Food and Drug Administration to make FRUZAQLA™ (fruquintinib) available on the US market.
The drug has been approved for use in patients as part of a treatment protocol that gives them another chance when other treatments such as chemotherapy have proven ineffective. The development partnership with Takeda is part of a broader global partnership strategy. Achieving this watershed will trigger the delivery of sales royalties as well as a milestone payment as part of a deal that will total up to US$1.13 billion.
